Search research articles
Contact Us
Filters
Showing results (41-50 of 185) with videos related to
Page
of 19
Sort By:
Annals of Nuclear Medicine
|
February 25, 2026
[<sup>11</sup>C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma
Elgin Ozkan, Burak Demir, Guldane Cengiz Seval, et al.
Blood Advances
|
July 18, 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Meletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 14, 2023
A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset
Meral Beksac, Hasan Yalim Akin, Guldane Cengiz Seval, et al.
The Lancet. Oncology
|
February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial
Birte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
International Journal of Hematology
|
April 15, 2025
Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study
Kihyun Kim, Estelle Verburgh, Tatiana Mitina, et al.
Leukemia & Lymphoma
|
November 9, 2018
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
Katja Weisel, Pieter Sonneveld, Andrew Spencer, et al.
Haematologica
|
May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Meletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Ejhaem
|
December 5, 2022
Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial
Andrew Spencer, Olga Samoilova, Wee-Joo Chng, et al.
Stem Cell Reviews and Reports
|
May 4, 2012
Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells
Mevci Ozdemir, Ayhan Attar, Isinsu Kuzu, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 185) with videos related to
Sort By:
Page
of 19
Annals of Nuclear Medicine
|
February 25, 2026
[<sup>11</sup>C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma
Elgin Ozkan, Burak Demir, Guldane Cengiz Seval, et al.
Blood Advances
|
July 18, 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Meletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, et al.
Leukemia & Lymphoma
|
February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 14, 2023
A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset
Meral Beksac, Hasan Yalim Akin, Guldane Cengiz Seval, et al.
The Lancet. Oncology
|
February 2, 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial
Birte Friedrichs, André Tichelli, Andrea Bacigalupo, et al.
International Journal of Hematology
|
April 15, 2025
Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study
Kihyun Kim, Estelle Verburgh, Tatiana Mitina, et al.
Leukemia & Lymphoma
|
November 9, 2018
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis
Katja Weisel, Pieter Sonneveld, Andrew Spencer, et al.
Haematologica
|
May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Meletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Ejhaem
|
December 5, 2022
Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial
Andrew Spencer, Olga Samoilova, Wee-Joo Chng, et al.
Stem Cell Reviews and Reports
|
May 4, 2012
Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells
Mevci Ozdemir, Ayhan Attar, Isinsu Kuzu, et al.
Page
of 19